Nanjing AscendRare Pharmaceutical Technology Co., Ltd is one of the spin-off companies from the Nanjing Institute of Advanced Biotechnology and Life Science, Nanjing’s new research and development institute. The company mainly conducts research on the treatment of hypoglycemia and diabetes, translational medicine, and the development of new drugs.
The company’s research focuses on islet function regulation and diseases related to abnormal islet function.
Hypoglycemia is a serious neonatal disease. Excessive or inappropriate secretion of insulin results in persistent hyperinsulinemic hypoglycemia. Hypoglycemia is mainly caused by mutations in genes that regulate some key enzymes or pathways in the process of insulin secretion. It is considered a rare disease.
Children with hyperinsulinemic hypoglycemia can live long and fulfilling lives, and the disease occurs less frequently in adults. Without timely and effective intervention, hypoglycemia is life-threatening and can cause irreversible brain damage.